Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACELYRIN, Inc.SLRN · Entity 79310 | CFO and CBO | August 31, 2024 | September 04, 2024 |
| NEKTAR THERAPEUTICSNKTR · Entity 4364 | SVP, COO & CFO | May 15, 2022 | May 18, 2022 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Septerna, Inc.SEPN · Entity 2452 | Chief Financial Officer | February 06, 2026 | February 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACELYRIN, Inc.
Report date August 31, 2024 · Filed September 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.78 · Expires 2034-08-30 | Direct | 150,000 |
Reported balance
After 2024-08-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-31 · Grant · Acquired 150,000 · Balance 150,000 F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4 of the shares subject to the option vest on August 31, 2025, and 1/48 of the shares subject to the option vest in equal monthly installments thereafter, subject to the Reporting Person's continued service.
NEKTAR THERAPEUTICS
Report date May 15, 2022 · Filed May 18, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 330,353 |
Reported balance
After 2022-05-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-05-15 · Grant · Acquired 28,750 · Balance 330,353 F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
| Common StockSEC Table I · non-derivative | Direct | 312,905 |
Reported balance
After 2022-05-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2022-05-16 · Sale · Disposed 17,448 · Balance 312,905 F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 14, 2018 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
F2: The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on May 13, 2022. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (May 15, 2022) following the date that the performance-based vesting requirement was satisfied.
F3: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
F4: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F5: This transaction was executed in multiple trades at prices ranging from $3.86 to $4.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 55,500 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 55,500 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
| Common SharesSEC Table I · non-derivative | IndirectThe Labrucherie Trust dated 9/1/2009 | 53,572 |
Reported balance
Holding disclosure · report date 2025-11-19 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 53,572 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Septerna, Inc.
Report date February 06, 2026 · Filed February 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.41 · Expires 2036-02-05 | Direct | 125,000 |
Reported balance
After 2026-02-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-06 · Grant · Acquired 125,000 · Balance 125,000 F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 2/48th of the shares subject to such option shall vest and become exercisable on March 1, 2026 and the remaining shares subject to the option shall vest in 46 substantially equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 18, 2020 Filed Dec 22, 2020 23:48 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,500 | $0.00 Strike: $18.75 | $0.00 |
DisclosureSEC source: 0001209191-20-064913 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,500 Underlying: Common Stock · 71,500 shares Expires 2028-12-17 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 18, 2020 Filed Dec 22, 2020 23:48 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064913 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 266,973 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2020 Filed Nov 19, 2020 00:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,276 | $16.93 | $140,112.68 |
DisclosureSEC source: 0001209191-20-059241 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,973 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $16.71 to $17.46. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| September 17, 2020 Filed Sep 22, 2020 00:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,000 | $19.96 | $39,920.00 |
DisclosureSEC source: 0001209191-20-051389 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,249 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.90 to $20.28. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 18, 2020 Filed Aug 19, 2020 22:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,000 | $19.68 | $39,360.00 |
DisclosureSEC source: 0001209191-20-047613 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 237,249 F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 22:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,245 | $19.67 | $122,839.15 |
DisclosureSEC source: 0001209191-20-047613 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 239,249 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $19.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 19, 2020 Filed May 20, 2020 22:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 2,000 | $22.62 | $45,240.00 |
DisclosureSEC source: 0001209191-20-031014 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,494 F4 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 18, 2020 Filed May 20, 2020 22:29 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,727 | $22.51 | $128,914.77 |
DisclosureSEC source: 0001209191-20-031014 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,494 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.29 to $22.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:37 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,938 | $22.35 | $132,714.30 |
DisclosureSEC source: 0001209191-20-011258 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,221 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $22.00 to $23.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 29,000 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060787 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 29,000 shares Expires 2017-12-11 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 71,550 | $0.00 Strike: $21.79 | $0.00 |
DisclosureSEC source: 0001209191-19-060787 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,550 Underlying: Common Stock · 71,550 shares Expires 2027-12-11 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 12, 2019 Filed Dec 17, 2019 02:34 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 40,150 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-060787 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,159 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 18, 2019 Filed Nov 21, 2019 00:04 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 8,863 | $17.97 | $159,268.11 |
DisclosureSEC source: 0001209191-19-057489 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,009 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.56 to $19.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-056807 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $19.79 | $494,750.00 |
DisclosureSEC source: 0001209191-19-056807 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,872 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $19.35 to $20.24. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 13, 2019 Filed Nov 15, 2019 23:09 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-056807 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-053497 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $15.83 | $395,750.00 |
DisclosureSEC source: 0001209191-19-053497 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,872 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 15, 2019 Filed Oct 17, 2019 22:59 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-053497 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $18.43 | $0.00 |
DisclosureSEC source: 0000899243-19-024776 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-30 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| October 01, 2019 Filed Oct 2, 2019 23:30 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-024776 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP, COO & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,872 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-050149 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $20.52 | $513,000.00 |
DisclosureSEC source: 0001209191-19-050149 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,872 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $20.05 to $20.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-050149 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $16.31 | $0.00 |
DisclosureSEC source: 0001209191-19-047553 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,500 Underlying: Common Stock · 30,000 shares Expires 2022-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 26, 2019 Filed Aug 27, 2019 21:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $16.31 | $489,300.00 |
DisclosureSEC source: 0001209191-19-047553 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 23:07 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 5,063 | $18.15 | $91,893.45 |
DisclosureSEC source: 0001209191-19-046715 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,872 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.87 to $18.37. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-046428 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $17.79 | $444,750.00 |
DisclosureSEC source: 0001209191-19-046428 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,935 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $17.31 to $18.64. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 14, 2019 Filed Aug 17, 2019 00:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-046428 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 22:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-041988 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 22:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $34.57 | $864,250.00 |
DisclosureSEC source: 0001209191-19-041988 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,935 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $34.10 to $35.03. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 22:31 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-041988 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $7.21 | $0.00 |
DisclosureSEC source: 0001209191-19-038099 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 25,000 shares Expires 2020-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 25,000 | $33.71 | $842,750.00 |
DisclosureSEC source: 0001209191-19-038099 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,935 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F3 · price: This transaction was executed in multiple trades at prices ranging from $33.37 to $33.91. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| June 17, 2019 Filed Jun 19, 2019 21:50 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 25,000 | $7.21 | $180,250.00 |
DisclosureSEC source: 0001209191-19-038099 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Labrucherie for stock options scheduled to expire on February 7, 2020. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2019 Filed May 18, 2019 00:20 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,767 | $31.37 | $118,170.79 |
DisclosureSEC source: 0001209191-19-031187 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,935 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $30.86 to $32.68. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| February 19, 2019 Filed Feb 22, 2019 01:14 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 3,592 | $42.39 | $152,264.88 |
DisclosureSEC source: 0001209191-19-012334 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,702 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.90 to $42.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 58,100 | $0.00 Strike: $36.51 | $0.00 |
DisclosureSEC source: 0001209191-18-063300 · doc4.xml · derivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,100 Underlying: Common Stock · 58,100 shares Expires 2026-12-13 F3 · derivative.exercise_date: This stock option vests over four years in equal monthly installments based on continued service. Read SEC document |
| December 14, 2018 Filed Dec 18, 2018 23:12 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 28,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-063300 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,294 F1 · security: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock. These RSUs vest over three years in substantially equal quarterly installments based on continued service. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| November 16, 2018 Filed Nov 19, 2018 23:13 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 6,515 | $38.25 | $249,198.75 |
DisclosureSEC source: 0001209191-18-059290 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,544 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $37.47 to $38.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 16, 2018 Filed Aug 17, 2018 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Disposition to issuerCommon Stock | 8,207 | $58.40 | $479,288.80 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · nonDerivative · entry 2 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,059 F3 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F4 · price: This transaction was executed in multiple trades at prices ranging from $56.37 to $59.72. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantStock Option · Derivative | 65,000 | $0.00 Strike: $56.90 | $0.00 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2025-12-14 F5 · security: These options, at the time of their grant were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a monthly pro-rata basis over a period of four years from the grant date (December 15, 2017). F6 · date: These stock options were granted on December 15, 2017 and the performance-based vesting requirement for these stock options was satisfied on August 15, 2018 upon the Compensation Committee's certification of the successful acceptance of the New Drug Application by the FDA for NKTR-181. F7 · derivative.exercise_date: This stock option vests on a monthly pro-rata basis over a period of four years from the grant date. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:45 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | GrantCommon Stock | 26,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-047241 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,266 F1 · security: Represents restricted stock units ("RSUs"), convertible on a one-for-one basis into shares of Common Stock of the Company. These RSUs, at the time of their grant on December 15, 2017, were subject to both performance-based and time-based vesting requirements. On August 15, 2018, the performance-based condition vesting was satisfied. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 4,218 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 16, 2018 Filed May 18, 2018 23:03 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 4,941 | $83.39 | $412,029.99 |
DisclosureSEC source: 0001209191-18-031594 · doc4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,798 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: This transaction was executed in multiple trades at prices ranging from $81.35 to $84.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F3 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · derivative · entry 9 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $82.86 | $2,485,800.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 6 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,739 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F5 · price: This transaction was executed in multiple trades at prices ranging from $81.37 to $84.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 03, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionCommon Stock | 30,000 | $10.69 | $320,700.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 5 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,739 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
| May 02, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | Exercise / conversionStock Option · Derivative | 30,000 | $0.00 Strike: $10.69 | $0.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · derivative · entry 8 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2019-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. Read SEC document |
| May 02, 2018 Filed May 4, 2018 00:43 UTC | NEKTAR THERAPEUTICS NKTR · Entity 4364 | SaleCommon Stock | 30,000 | $85.63 | $2,568,900.00 |
DisclosureSEC source: 0001209191-18-027942 · doc4.xml · nonDerivative · entry 4 Labrucherie Gil M · CIK 0001394875 · SVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,739 F1 · security: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for options expiring in the next 12 months. F4 · price: This transaction was executed in multiple trades at prices ranging from $83.96 to $86.86. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer. F2 · balance_after: This number includes 997 shares held by the reporting person in the Issuer's 401(K) plan and 3,750 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.